Bad Food Fines? FDA Updates 2026 Reinspection Fees
Published Date: 7/30/2025
Notice
Summary
Starting in fiscal year 2026, the FDA is updating fees for checking food facilities again, handling recall slip-ups, and re-inspecting importers. If you run or import food businesses, expect some changes in costs and timing for these inspections. These updates help keep our food safe and make sure everyone plays by the rules.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 1 costs, 2 mixed.
Updated Fees for Facility Reinspections
If you run a domestic or foreign food facility, the FDA is updating the fees it charges for facility reinspections starting in fiscal year 2026. Expect changes in the costs and timing of these reinspections that affect businesses that operate or export food facilities.
Importer Reinspection Fee Changes
If you import food, the FDA is updating the fees for importer reinspections starting in fiscal year 2026. Importers should expect changes to inspection-related costs and possible timing impacts for imported food shipments.
Fees for Failure To Comply With Recall Orders
If you fail to comply with an FDA recall order, the agency is updating the fees for failures to comply starting in fiscal year 2026. Businesses subject to recall orders should expect updated financial penalties or fees tied to noncompliance.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2025-14413, Prescription Drug User Fee Rates for Fiscal Year 2026
The FDA is setting new fees for drug companies in fiscal year 2026 to help speed up the review of prescription drugs and biological products. If you’re a drug maker, expect some changes in how much you pay to get your products approved or stay on the market. These fees kick in starting October 1, 2025, so plan your budgets accordingly!
Next: 2025-14415, Food Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2026
Starting in fiscal year 2026, the FDA is updating the fees for groups that check food safety under the Food Safety Modernization Act. This affects accreditation and certification bodies who want to get or keep their official approval. The new fees help keep food safety checks strong and fair, with changes kicking in soon to keep everyone on track.